MS Franchise A Surprising Concern For Sanofi In Q3; Dupixent Out-Performs
Executive Summary
Sanofi produced a mixed financial performance in the third quarter of 2017, with reported sales more than €200m below analysts' expectations but new drug Dupixent doing well; MS drug sales have fallen since Q2 by more than €50m.
You may also be interested in...
European Nod For Roche’s Ocrevus Clouded By Patient Limitation
Swiss major Roche has finally got a positive opinion for its closely watched drug but concerns have been raised that Ocrevus will only be licensed for early-stage primary progressive multiple sclerosis patients.
Sanofi Expands MS Portfolio With BTK Inhibitor From Principia
The French pharma adds the Phase I candidate to its Lemtrada follow-on for multiple sclerosis development, while Principia will use $40m in upfront cash to advance its orphan disease strategy.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.